...ChAdOx1 or BNT162b2 vaccines already reduced SARS-CoV-2 infections ≥21 d after the first dose (61% ...versus 66%)..., after a second dose...(79% versus 80%)...respectively
...largest reductions...for symptomatic...and/or infections with a higher viral burden
1/5
...largest reductions...for symptomatic...and/or infections with a higher viral burden
1/5
https://twitter.com/NaturePortfolio/status/1405718412857331713
Overall,...largest benefit...after two vaccinations and against symptomatic and high viral burden infections, and with no evidence of a difference between the BNT162b2 and ChAdOx1 vaccines.
2/5
2/5
...benefits associated with vaccination were much greater for infection...with...high levels of viral shedding...estimated at 91%...post-second dose
...75%...effectiveness following one dose ≥21 d ago...
3/5
...75%...effectiveness following one dose ≥21 d ago...
3/5
...effects of vaccination on infections compatible and not compatible with the B.1.1.7 variant appeared similar, but small numbers of positives in the latter group led to large uncertainty in the estimates...
4/5
4/5
...no evidence that the vaccine effectiveness...differed between the BNT162b2 and ChAdOx1 vaccines..., whether the vaccine was received 0–7 d previously..., 8–20 d previously..., ≥21 d previously...or post-second dose
5/5
5/5
• • •
Missing some Tweet in this thread? You can try to
force a refresh
